DAVION HEALTHCARE PLC (DAVI)
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Davion Healthcare Plc
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 1.08 | 1.15 | 0.9365 | 1.03 | 186,360 |
| Nov 16, 2026 | 1.03 | 1.16 | 0.9901 | 1.02 | 333,462 |
| Nov 13, 2026 | 1.17 | 1.19 | 0.9140 | 1.00 | 331,501 |
| Nov 12, 2026 | 1.39 | 1.48 | 1.19 | 1.19 | 204,672 |
| Nov 11, 2026 | 1.54 | 1.56 | 1.32 | 1.39 | 294,135 |
| Nov 10, 2026 | 1.62 | 1.76 | 1.57 | 1.58 | 163,404 |
| Nov 9, 2026 | 1.63 | 1.80 | 1.50 | 1.75 | 269,691 |
| Nov 6, 2026 | 1.37 | 1.67 | 1.36 | 1.59 | 423,767 |
| Nov 5, 2026 | 1.59 | 1.63 | 1.31 | 1.31 | 241,416 |
| Nov 4, 2026 | 1.61 | 1.67 | 1.50 | 1.67 | 189,847 |
| Nov 3, 2026 | 1.43 | 1.61 | 1.40 | 1.54 | 366,320 |
| Nov 2, 2026 | 1.68 | 1.68 | 1.46 | 1.49 | 429,501 |
| Oct 30, 2026 | 2.24 | 2.24 | 1.65 | 1.68 | 1,401,826 |
| Oct 29, 2026 | 3.13 | 3.20 | 2.59 | 2.69 | 4,176,095 |
| Oct 28, 2026 | 3.72 | 3.81 | 2.95 | 3.29 | 8,533,316 |
| Oct 27, 2026 | 3.72 | 3.99 | 2.78 | 3.00 | 6,069,899 |
| Oct 26, 2026 | 4.86 | 4.91 | 3.91 | 4.07 | 380,799 |
| Oct 23, 2026 | 8.89 | 8.89 | 5.67 | 6.00 | 479,471 |
| Oct 22, 2026 | 12.25 | 12.30 | 9.52 | 11.65 | 558,418 |
| Name | Shares | % | Source |
|---|---|---|---|
Kaye Jack Harry CHIEF EXECUTIVE OFFICER, Director, 10% Owner | 5.2M | 20.7% | FORM 4 |
Insiders
- Kaye Jack HarryCHIEF EXECUTIVE OFFICER, Director, 10% Owner
Davion Healthcare Plc is an Irish public limited company that develops and commercializes non-invasive home tests for the early detection of health anomalies, including cancers.
Its products use thermography: a liquid crystal film placed on the skin shows temperature differences as color shifts, and AI analysis of smartphone images interprets the result.
It has four completed tests, BreastCheck, FootFlow (diabetic circulation), Testic and ThermaDerm, all non-diagnostic Class I devices. BreastCheck and FootFlow have been FDA-registered, and registered in the EU and UK, since November 2023. Davion operates a licensing model and has a global manufacturing and distribution agreement for BreastCheck with NeuRX Health Inc., which provides $120 million in staged license fees and minimum annual royalties of $10 million over an initial ten-year term.
The company was incorporated in Cyprus in 2022 and re-domiciled to Ireland in 2024, keeping a wholly owned Cyprus subsidiary.
It plans to pair product commercialization with acquisitions of complementary healthcare businesses, and has launched a £30 million five-year senior secured bond through Davion Healthcare Finance Ltd. The listing is a direct listing of 25,000,000 existing ordinary shares, with no new capital raised.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
30d Avg
1.32M
60d Avg
1.32M
90d Avg
1.32M
Signal8's dilution snapshot of DAVI as of Dec 31, 2025 records 1 outstanding warrant series and a PIPE closed Mar 10, 2026, from SEC filings. Davion Healthcare PLC (NASDAQ: DAVI) traded at $1.03 on Nov 17, 2026, up 0.98% from the previous close of $1.02. 52-week range: $0.9365 to $12.30. The company is in the Healthcare sector (Medical - Devices).